The Evolving Role of High‐Sensitivity C‐Reactive Protein for Mortality Prediction Across the Spectrum of Cardiovascular–Kidney–Metabolic Syndrome
Diabetes, Obesity and Metabolism · 2026
DOI: 10.1111/dom.70843 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, 2026. Verfasst von Jing Li und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology, Beijing Neurosurgical Institute, Beijing Tiantan Hospital, Capital Medical University, Beijing, China. Hauptthemen laut MEDLINE: C-Reactive Protein, Metabolic Syndrome, Cardio-Renal Syndrome, Cardiovascular Diseases. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: Outstanding Young Investigator Program of Capital Medical University.
Abstract (Originalsprache)
Aims
High‐sensitivity C‐reactive protein (hsCRP) is central to cardiovascular–kidney–metabolic (CKM) syndrome pathogenesis, but its prognostic value across progressive CKM stages remains uncertain. We aimed to evaluate the stage‐specific associations between hsCRP and mortality in CKM syndrome. Materials and Methods In this prospective analysis of 86 829 participants from the Kailuan Study, we evaluated hsCRP's association with all‐cause mortality stratified by AHA‐defined CKM stages (0–4). Multivariable Cox models assessed hazard ratios (HRs) for mortality per unit increase in ln(hsCRP) and by dichotomised hsCRP (< 2 vs. ≥ 2 mg/L).
Results
Over a median follow‐up of 16.01 years, 13 960 deaths occurred. HsCRP levels were associated with higher mortality across all stages, but the association progressively attenuated with advancing CKM stages. Adjusted HRs per ln(hsCRP) were 1.11 (95% CI: 1.03–1.20) in Stage 0, 1.14 (1.07–1.21) in Stage 1, 1.08 (1.06–1.10) in Stage 2, 1.05 (1.03–1.07) in Stage 3 and 1.04 (1.00–1.08) in Stage 4 ( p for interaction < 0.001). Similarly, dichotomised hsCRP showed declining mortality risks from Stage 0 (HR: 1.51, 1.15–1.98) to Stage 4 (HR: 1.07, 0.97–1.19). Restricted cubic splines confirmed this gradient, with early stages displaying steep risk curves that plateaued in advanced stages. Sensitivity analyses supported robustness.
Conclusions
The association of hsCRP with mortality diminishes with CKM syndrome progression, suggesting a shift from inflammation‐driven risk in early stages to complex multiorgan dysfunction in late stages. These findings advocate for stage‐specific risk assessment, with hsCRP retaining utility in early CKM management but requiring integrated approaches in advanced disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Epidemiology, Beijing Neurosurgical Institute, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
- China National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
- Department of Clinical Epidemiology and Clinical Trial, Capital Medical University, Beijing, China.
- Department of Epidemiology and Biostatistics, School of Public Health, Capital Medical University, Beijing, China.
- Department of Cardiology, Kailuan General Hospital, North China University of Science and Technology, Tangshan, Hebei, China.
ORCID-Profile: Xue Xia, Yuxiang Yan, Anxin Wang
Förderung
- Outstanding Young Investigator Program of Capital Medical University
Zitieren
APA
Li, J., Chen, S., Zhang, X., Xia, X., Yan, Y., Wu, S., & Wang, A. (2026). The Evolving Role of High‐Sensitivity C‐Reactive Protein for Mortality Prediction Across the Spectrum of Cardiovascular–Kidney–Metabolic Syndrome. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.70843
Vancouver
Li J, Chen S, Zhang X, Xia X, Yan Y, Wu S, et al. The Evolving Role of High‐Sensitivity C‐Reactive Protein for Mortality Prediction Across the Spectrum of Cardiovascular–Kidney–Metabolic Syndrome. Diabetes, Obesity and Metabolism. 2026. doi:10.1111/dom.70843
BibTeX
@article{Li2026,
author = {Li, Jing and Chen, Shuohua and Zhang, Xiaoli and Xia, Xue and Yan, Yuxiang and Wu, Shouling and Wang, Anxin},
title = {The Evolving Role of High‐Sensitivity C‐Reactive Protein for Mortality Prediction Across the Spectrum of Cardiovascular–Kidney–Metabolic Syndrome},
journal = {Diabetes, Obesity and Metabolism},
year = {2026},
doi = {10.1111/dom.70843}
}
EUVIMED